Erlotinib hydrochloride and Left ventricular dysfunction - a phase IV clinical study of FDA data

Summary:

Left ventricular dysfunction is reported as a side effect among people who take Erlotinib hydrochloride (erlotinib hydrochloride), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Dilaudid, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Left ventricular dysfunction when taking Erlotinib hydrochloride. It is created by eHealthMe based on reports of 4,643 people who have side effects when taking Erlotinib hydrochloride from the FDA, and is updated regularly.

What is Erlotinib hydrochloride?

Erlotinib hydrochloride has active ingredients of erlotinib hydrochloride. eHealthMe is studying from 4,663 Erlotinib hydrochloride users. Check the latest studies of Erlotinib hydrochloride.

What is Left ventricular dysfunction?

Left ventricular dysfunction is found to be associated with 891 drugs and 792 conditions by eHealthMe. Check the latest studies of Left ventricular dysfunction.

On Jul, 09, 2026

4,643 people reported to have side effects when taking Erlotinib hydrochloride.
Among them, 18 people (0.39%) have Left ventricular dysfunction.

Could Erlotinib hydrochloride cause Left ventricular dysfunction?

Among these 18 people:

How long have people been on Erlotinib hydrochloride when they have Left ventricular dysfunction? *

What is the gender of people who have Left ventricular dysfunction when taking Erlotinib hydrochloride? *

female: 44.44 %
male: 55.56 %

What is the age of people who have Left ventricular dysfunction when taking Erlotinib hydrochloride? *

What are other drugs people take besides Erlotinib hydrochloride? *

What are other side effects people have besides Left ventricular dysfunction? *

Pneumonia: 6 people, 33.33%
Arteriospasm Coronary (spasm of the large- or medium-sized coronary arteries): 4 people, 22.22%
Nausea (feeling of having an urge to vomit): 3 people, 16.67%
Sinus Tachycardia (a heart rhythm with elevated rate of impulses originating from the sinoatrial node): 3 people, 16.67%
Blood Albumin Decreased: 3 people, 16.67%
Lymphocyte Count Decreased: 3 people, 16.67%
Hypotension (abnormally low blood pressure): 3 people, 16.67%
Tricuspid Valve Incompetence (inefficient heart valve): 3 people, 16.67%
White Blood Cell Count Decreased: 3 people, 16.67%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 3 people, 16.67%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 10 people, 55.56%
Type 2 Diabetes: 2 people, 11.11%
Neoplasm Malignant (cancer tumour): 2 people, 11.11%
High Blood Pressure: 2 people, 11.11%
Fever: 2 people, 11.11%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 2 people, 11.11%
Asthma: 2 people, 11.11%
Pancreatic Carcinoma (pancreatic cancer): 1 person, 5.56%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 5.56%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Erlotinib hydrochloride and have Left ventricular dysfunction?

- Check whether Left ventricular dysfunction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erlotinib hydrochloride:

Erlotinib hydrochloride (4,663 reports)

Browse all side effects of Erlotinib hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Left ventricular dysfunction:

Left ventricular dysfunction (891 drugs)

Browse all the conditions that are associated with Left ventricular dysfunction:

Left ventricular dysfunction (792 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Erlotinib hydrochloride) and Erlotinib hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.